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Atrial Fibrillation and Brugada Syndrome
Johnson Francis, MD, DM, FCSI, FACC,* Charles Antzelevitch, PHD, FACC, FAHA, FHRS†
Kerala, India; and Utica, New York
Brugada syndrome is characterized by right bundle branch block pattern with ST-segment elevation in leads V1
to V3 and a propensity for sudden cardiac death due to ventricular arrhythmias. The arrhythmogenic substrate in
Brugada syndrome may not be restricted to the ventricles, and atrial arrhythmias are being increasingly re-
ported. Incidences of spontaneous atrial arrhythmias vary from 6% to 38% and those of inducible atrial arrhyth-
mias from 3% to 100%. Atrial fibrillation (AF) is the most common atrial arrhythmia found in Brugada syndrome. En-
hanced duration of atrial action potential and increased intra-atrial conduction time may contribute to the genesis of
atrial arrhythmias in Brugada syndrome. Atrial arrhythmias are an important cause of inappropriate discharge of im-
plantable defibrillators in patients with Brugada syndrome. Hence, implantation of dual-chamber defibrillators and
careful programming of single-chamber devices have been recommended. Atrial fibrillation has been associated with
mutations in both the sodium and calcium channels of the heart, as well as with cases of Brugada syndrome that
could not genotyped to any of the known genes associated with the disease. This observation suggests that the sub-
strate responsible for the development of ventricular arrhythmias also may contribute to arrhythmogenesis in the
atria of the heart. The presence of a prominent transient outward current in atria and the observation that episodes of
AF are triggered by closely coupled atrial extrasystoles point to the possibility that a substrate similar to that responsi-
ble for ventricular arrhythmogenesis underlies the development of AF in patients with Brugada syndrome. (J Am
Coll Cardiol 2008;51:1149–53) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.062s
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erugada syndrome is characterized by right bundle branch
lock pattern and ST-segment elevation in precordial leads
1 to V3 on electrocardiogram (ECG) and a propensity for
udden cardiac death (1). Several studies have linked the
enetic basis of Brugada syndrome to mutations in the gene
hat encode the  subunit of the sodium channel (2). More
ecent studies have linked the syndrome to mutations in
enes that encode the  and  subunits of the calcium
hannel (3) and the gene that encodes glycerol-3-phosphate
ehydrogenase 1-like enzyme (GPD1L) (4). The 4 genes
hus far identified are estimated to account for approximately
8% of Brugada syndrome probands. Accordingly, 72% of
ases remain unaccounted for by genotype. Life-threatening
entricular arrhythmias are the hallmarks of Brugada syn-
rome. The arrhythmogenic substrate in Brugada syndrome
ay not be restricted to the ventricular level. Similar changes
ccur in the atria and could be the substrate for re-entrant atrial
achyarrhythmias. Atrial arrhythmias are being increasingly
ecognized in patients with Brugada syndrome. Incidences of
pontaneous atrial arrhythmias between 6% and 38% have been
eported. The inducibility of atrial arrhythmias has ranged
rom 3% to 100% (Table 1) (5–15). Bordachar et al. (9) have
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ccepted October 29, 2007.uggested that the disease process is more advanced in Brugada
yndrome patients with atrial arrhythmias. One of the larg-
st studies that has reported on atrial arrhythmias in Brugada
yndrome is from Sacher et al. (11). Thirty-two of their 220
atients had supraventricular arrhythmias, with 23 of them
10% of patients) having atrial fibrillation (AF). This was a
etrospective evaluation of Brugada syndrome patients with an
mplantable cardioverter-defibrillator (ICD) from 14 centers.
Atrial fibrillation is the most common atrial arrhythmia
ound in Brugada syndrome, although a few cases of associated
trioventricular nodal re-entrant and atrioventricular re-entrant
achycardia with accessory pathway have also been noted (12).
ome studies have reported prolongation of atrio His and
is ventricular (HV) interval; these changes occur princi-
ally in patients with SCN5A mutations (16) and are
onsistent with a decreased excitability in the conduction
ystem secondary to the loss of function of sodium channel
ctivity. Vagal activity is believed to contribute to the ST-
egment elevation and slower atrioventricular conduction in
rugada syndrome as well as in the initiation of paroxysmal AF
7). Bordachar et al. (9) noted that patients with an HV
nterval55 ms had significantly more atrial arrhythmias than
hose with a normal HV interval (66% vs. 8.5%; p  0.001).
linical predictors of AF in Brugada syndrome. Bigi et
l. (15) studied the clinical predictors of AF in Brugada
yndrome. Of the 28 patients with Type 1 ST-segment
levation ECG pattern, 15 had paroxysmal AF. All of them
ad previous life-threatening cardiac events (8 had syncope,
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AF and the Brugada Syndrome March 25, 2008:1149–532 had ventricular fibrillation, 4 had
polymorphic ventricular tachycar-
dia, and 1 had aborted sudden
cardiac death). Multiple regression
analysis did not show any correla-
tion between various parameters
such as left atrial size, age, and
P-wave dispersion.
Noninvasive evaluation. The
atrial arrhythmias are triggered
by atrial premature beats as ob-
erved on Holter recordings of the arrhythmia. The
rematurity and P-on-T morphology of these beats also
uggest a pulmonary vein focus (9) or phase 2 re-entry
echanism. The presence of atrial arrhythmias has been
orrelated with inducible ventricular arrhythmias in patients
ith Brugada syndrome. Patients with a spontaneous
rugada-type ECG are more likely to have atrial arrhyth-
ias than those who manifest the pattern only on challenge
ith drugs like flecainide. Greater incidences of atrial
rrhythmias have also been noted in patients with ICDs
han those without, presumably because the former were
mplanted ICDs because of risk factors for sudden cardiac
eath and more severe form of Brugada syndrome (9).
Signal-averaged ECG has been used to assess the vulner-
bility to AF. The filtered P-wave duration is prolonged in
atients with Brugada syndrome. In one study (9), the mean
ltered P-wave duration was 143.2  12.9 ms in patients
ith Brugada syndrome and 129.6  10.1 ms in controls (p
0.01). Similar findings were reported by Osaka et al. (17)
n their study; mean filtered P-wave duration was 143.7 
0.3 ms in patients versus 122.3  9.9 ms in controls (p 
.0001).
nvasive electrophysiologic evaluation. Atrial vulnerabil-
ty is enhanced in Brugada syndrome, as documented by
lectrophysiologic studies. The duration of atrial action po-
ential is prolonged (80.3 18.0 ms in patients vs. in controls
9.3 9.2 ms, p 0.001) (12). As discussed herein, although
n association between prolonged atrial action potentials and
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram
HV  His ventricular
ICD  implantable
cardioverter-defibrillator
INa  sodium channel
current
Incidence of Atrial Arrhythmias in Brugada Synd
Table 1 Incidence of Atrial Arrhythmias in B
Author Year
No. of
Patients
Eckardt et al. (5) 2001 35
Itoh et al. (6) 2001 30
Morita et al. (7) 2002 18
Park et al. (8) 2003 15
Bordachar et al. (9) 2004 59
Junttila et al. (10) 2004 18
Sacher et al. (11) 2006 220
Yamada et al. (12) 2006 11
Kharazi et al. (13) 2007 12
Miyamoto et al. (14) 2007 98Bigi et al. (15) 2007 28F seems counterintuitive, the increased vulnerability of the
trium may be secondary to a concomitant increase in disper-
ion of repolarization and refractoriness, as occurs in the
entricular myocardium. This hypothesis is among many that
emain to be tested. Increased intra-atrial conduction time also
ay contribute to the genesis of atrial arrhythmias. Morita et
l. (7) reported that right atrial effective refractory period is not
rolonged in Brugada syndrome but that intra-atrial conduc-
ion time is significantly increased (168.4  17.5 ms vs. 131.8
13.0 ms, p  0.001).
Induction of AF with programmed extrastimulation of
he atria in patients without the spontaneous clinical ar-
hythmia also has been noted. All 11 patients studied by
amada et al. (12) had AF induced by a protocol using up
o 2 extrastimuli from the high right atrium. The mean right
trial refractory period at a cycle length of 600 ms was 196.6
28.3 (160 to 240) ms in these patients, which was not
ignificantly different from controls (206.6  22.3 [170 to
45] ms). Other studies using single extrastimuli reported a
uch lower rate of induction of AF. Eckardt et al. (5) could
nduce AF in only one of the 35 patients studied, though 9
thers developed other supraventricular arrhythmias with a
ingle atrial extra stimulus. In the series reported by Morita
t al. (7), AF was induced in 8 of 14 patients (57%) with
ingle extrastimuli. In both of these series, patients dis-
layed clinical episodes of AF. Moriata et al. (7) reported 8
atients with inducible AF; 6 did not have spontaneous AF,
nd 1 of the 7 patients with spontaneous AF did not have
nducible AF. They defined inducible AF as one that was
recipitated with programmed electrical stimulation and
ersisted for at least 30 s. In one of their patients, AF also
as induced by isoproterenol infusion. An important limi-
ation of these studies is that induced AF is a weak surrogate
or the clinical arrhythmia.
ignificance of AF in Brugada syndrome patients receiv-
ng an ICD. Atrial arrhythmias are an important cause of
nappropriate ICD shocks in patients with Brugada syndrome.
n one study, the number of inappropriate shocks (14%)
xceeded the number of appropriate shocks (10.5%) (8).
da Syndrome
Incidence of Atrial Arrhythmias
Total
Atrial Fibrillation
Spontaneous Inducible
29% — 3% (1/35)
30% 30% (9/30) —
— 39% (7/18) 57% (8/14)
40% 27% (4/15) 8% (1/13)
20% 17% (12/59) —
6% 6% (1/18) —
15% 10% (23/220) —
100% 0 100% (11/11)
17% 17% (2/12) —
20% 20% (20/98) —rome
ruga53% 53% (15/28) —
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March 25, 2008:1149–53 AF and the Brugada Syndromeual-chamber ICDs are useful in preventing such inappro-
riate shocks in patients with paroxysmal AF, but this has to
e weighed against the increased complication rate associ-
ted with the atrial lead placement. Another, less invasive
nd, at times, simpler option is the use of rate-lowering
rugs. Careful programming of single-chamber ICDs also is
ecommended to avoid inappropriate shocks in those with-
ut documented AF. Kharazi et al. (13) reported similar
ndings. In their study, 41% had inappropriate shocks
hereas 17% had appropriate shocks. Of the 5 patients who
ad inappropriate shocks, 2 had AF. Sacher et al. (11) also
ound that inappropriate shocks were 2.5 times more
ommon than appropriate ones. In their study, supraven-
ricular arrhythmia was the reason for shock only in 9 of the
5 patients who received inappropriate shocks. One hun-
red ninety-six of their patients have received single-
hamber ICD and 24 received dual-chamber devices.
enetic basis. The past decade has witnessed steady
rogress in our ability to elucidate the genetic basis of the
rugada syndrome. SCN5A, the gene that encodes the
subunit of the cardiac sodium channel, was the first gene
inked to Brugada syndrome. (2) More than one-hundred
utations in SCN5A have been linked to the syndrome in
ecent years (18). Some of these mutations have been
tudied in expression systems and shown to result in loss of
unction due either to: 1) failure of the sodium channel to
xpress; 2) a shift in the voltage- and time-dependence of
odium channel current (INa) activation, inactivation, or
eactivation; 3) entry of the sodium channel into an inter-
ediate state of inactivation from which it recovers more
lowly; or 4) accelerated inactivation of the sodium channel.
utations in the SCN5A gene account for approximately
5% of Brugada syndrome probands (3,19,20). A greater
ncidence of SCN5A mutations has been reported in familial
han in sporadic cases (20). Negative SCN5A results do not
ule out causal gene mutations, because the promoter
egion, cryptic splicing mutations or presence of gross
earrangements are generally not part of routine investiga-
ion. Hong et al. (21) provided the first report of a
ysfunctional sodium channel created by an intronic muta-
ion giving rise to cryptic splice site activation in SCN5A in
family with the Brugada syndrome. The deletion of
ragments of segments 2 and 3 of domain IV of SCN5A
aused complete loss of function. Bezzina et al. (22) recently
rovided interesting evidence in support of the hypothesis
hat SCN5A promoter polymorphism common in Asians
odulate cardiac conduction, and may contribute to the
igh prevalence of Brugada syndrome in the Asian popula-
ion. Sequencing of the SCN5A promoter identified a
aplotype variant consisting of 6 polymorphisms in near-
omplete linkage disequilibrium that occurred at an allele
requency of 22% in Asian subjects and was absent in white
nd black patients. The results of the study demonstrate that
odium channel transcription in the human heart may vary
onsiderably among individuals and races and be associated
ith variable conduction velocity and arrhythmia suscepti- sility. A second locus on chromosome 3, close to but
istinct from SCN5A, has recently been linked to the
yndrome (23) in a large pedigree in which the syndrome is
ssociated with progressive conduction disease, a low sen-
itivity to procainamide, and a relatively good prognosis.
he gene recently was identified as the GPD1L. A muta-
ion in GPD1L has been shown to result in a reduction of
Na (4). The third and fourth genes associated with the
rugada syndrome were reported earlier this year and shown
o encode the 1 (CACNA1C) and  (CACNB2b) sub-
nits of the L-type cardiac calcium channel. Mutations in
he  and  subunits of the calcium channel can also lead to
shorter than normal QT interval, creating a new clinical
ntity consisting of a combined Brugada/short-QT syn-
rome (3). Because the genetic basis of all cases of Brugada
yndrome have not been identified in approximately 72% of
robands, defects other than sodium channel, calcium
hannel, or GPD1L also could cause Brugada syndrome.
Atrial fibrillation has been associated with mutations in
oth the sodium and calcium channels of the heart, as well
s with cases of Brugada syndrome that could not be
enotyped to any of the known genes associated with the
isease (3,24). This observation suggests that the substrate
esponsible for the development of ventricular arrhythmias
lso may contribute to arrhythmogenesis in the atria of the
eart.
ellular and ionic mechanisms. The available data sup-
ort the hypothesis that the electrocardiographic and ven-
ricular arrhythmic manifestations of Brugada syndrome
esult from amplification of heterogeneities intrinsic to the
arly phases of the action potential among the different
entricular cell types. The amplification is secondary to a
ebalancing of currents active during phase 1, including a
ecrease in INa or calcium channel current or augmentation
f any one of a number of outward currents. ST-segment
levation similar to that observed in patients with the
rugada syndrome occurs as a consequence of the accentu-
tion of the action potential notch, eventually leading to loss
f the action potential dome in right ventricular epicardium,
here transient outward current (Ito) is most prominent.
oss of the dome gives rise to both a transmural as well as
picardial dispersion of repolarization. The transmural dis-
ersion is responsible for the development of ST-segment
levation and the creation of a vulnerable window across the
entricular wall, whereas the epicardial dispersion give to
hase 2 re-entry, which provides the closely coupled extra-
ystole that captures the vulnerable window, thus precipi-
ating ventricular tachycardia/ventricular fibrillation. The
resence of a prominent Ito appears to be a prerequisite for
hese mechanisms to evolve and presence of a prominent Ito
n the right ventricular epicardium forms the basis for why
he Brugada syndrome is a right ventricular disease (25).
The presence of a prominent Ito in atria and the obser-
ation that episodes of AF are triggered by closely coupled
trial extrasystoles point to the possibility that a substrate
imilar to that responsible for ventricular arrhythmogenesis
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AF and the Brugada Syndrome March 25, 2008:1149–53nderlies the development of AF in patients with Brugada
yndrome. Additional research is clearly needed to examine the
alidity of this hypothesis. Relevant to this issue is a recent
eport demonstrating a major difference in the electrophysiol-
gy of atrial and ventricular sodium channels in the canine
eart. These studies indicate that steady-state inactivation V0.5
s 16 mV more negative in atrial than in ventricular cells,
endering a large fraction of sodium channels unavailable at the
ormal resting membrane potential (26,27). An intrinsically
ore positive resting membrane potential in atria (approxi-
ately 83 mV) versus ventricles (approximately 87 mV)
ontributes to the atrioventricular difference in sodium channel
vailability. These findings suggest that the impact of some
CN5A mutations may be greater in the atria than in the
entricles, and thus may predispose to the development of AF
ore readily than to ventricular arrhythmias.
Although genetic mutations responsible for the Brugada
yndrome are equally distributed between men and women,
he Brugada phenotype is generally 8 to 10 times more
revalent in men than in women. The basis for this
ender-related distinction has been shown to be due to a
ore prominent Ito, giving rise to a more prominent action
otential notch in the right ventricular epicardium of men
ersus women (28). It is not clear whether this gender
istinction extends also to the prevalence of AF. Studies in
hich an association of AF with Brugada syndrome has
een evaluated have involved mostly males. All patients in
he series reported by Morita et al. (7) and Yamada et al.
12), both with and without AF, were men. The vast
ajority of Brugada patients in the series reported by Itoh
t al. (6), and Park et al. (8) also were men.
The extent to which SCN5A mutations apparently unre-
ated to Brugada syndrome may be associated with AF is not
ell defined. It is noteworthy that mutations in SCN5A
ssociated with AF have been reported in relatives of probands
ith idiopathic dilated cardiomyopathy. In the study of Olson
t al. (29), among family members with SCN5A mutations,
8% had dilated cardiomyopathy (mean age at diagnosis was
7.9 years) and 43% had AF (mean age at diagnosis was 27.8
ears). It would be of interest to conduct a similar study with
amilies of probands with Brugada syndrome.
tudy limitations. Many of the large series of patients with
rugada syndrome do not report the incidence or charac-
eristics of atrial arrhythmias, for example, Brugada et al.
30), 547 patients; Eckardt et al. (31), 212 patients; Priori et
l. (32), 200 patients. The only large study that reported on
trial arrhythmia was the retrospective analysis by Sacher et
l. (11) of 220 Brugada syndrome patients with an implant-
ble defibrillator. Because of the retrospective nature of the
tudy, no electrophysiological data on AF are available from
his study. Hence, larger studies with prospective and
etailed evaluation of AF and other atrial arrhythmias in
rugada syndrome are needed to establish the link between
he two. Another limitation is that AF often occurs without
ymptoms, even in “symptomatic” patients and it is likely
hat there is an underestimation of the “true” AF rate.The degree to which AF is inducible in patients with
rugada syndrome also may be underestimated because
ymptomatic patients with Brugada syndrome as a general
ule do not undergo electrophysiological testing. The second
onsensus report published in 2005 recommended electro-
hysiological testing of symptomatic patients for the express
urpose of assessing the potential for supraventricular ar-
hythmias (25,33).
eprints requests and correspondence: Dr. Johnson Francis,
rofessor of Cardiology, Calicut Medical College, Calicut, Kerala,
ndia. E-mail: francisj@cmc.edu.in.
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